Stock search

Ticker or company name

Regeneron Pharmaceuticals

REGN · NASDAQ · Biotechnology

$952,40Down −3,07 (−0,32%)today

Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time

Market cap
$99,5 bn
Div. yield
—
Year to date
+23,8%
52 weeks: $591,52$991,73

Ratio score

67/100
Ratio would watch

based on 9 metrics as of 16.11.2026 ·

Verdict by our methodology based on current metrics. Not an investment recommendation.

Key metrics

5 ✓ · 2 — · 2 ✕ · 1 n/a · hover over a row or tap it to see the trend

All metrics

MetricValue5-year medianIndustry median
P/E TTM20,517,942,1
Forward P/E13,8—18,7
PEG1,2—4,1
P/S5,85,56,6
EV/EBITDA18,216,428,2
P/FCF27,2—26,0
P/B3,03,49,8

Industry median — across 6 profitable companies in “Biotechnology” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.

Price chart

Compare with

Choose a stock

Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.

Analysts

Ratings, 36 analysts

Buy
26
Hold
10
Sell
0

Beat the EPS forecast in 4 of the last 4 quarters

QuarterEstimateActualSurprise
Q3 202616,5620,07Up +21,2%
Q2 202610,4714,29Up +36,5%
Q1 20269,129,47Up +3,9%
Q4 202510,8311,44Up +5,7%

Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.

Financials in charts

MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Revenue5,12 bn4,29 bn3,61 bn3,88 bn3,75 bn3,68 bn3,03 bn3,79 bn3,72 bn3,55 bn3,15 bn3,43 bn
EPS18,4512,236,757,8713,6212,817,278,1111,5412,416,2710,20
Margin38,1%30,2%20,2%21,7%38,9%37,9%26,7%24,2%36,0%40,4%23,0%33,8%
FCF1,48 bn573 m848 m922 m1,42 bn925 m816 m1,06 bn1,05 bn174 m1,38 bn838 m

From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.

Owners

Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.

Insider trades over 12 months

Over 12 months: no purchases, sales $57,9 m.

NameAmountSharesPrice
pitofsky jason4 Nov 2026 · sale$170 186179$950,76
pitofsky jason4 Nov 2026 · sale$33 09635$945,61
pitofsky jason4 Nov 2026 · sale$101 976108$944,22
pitofsky jason4 Nov 2026 · sale$499 127529$943,53
pitofsky jason4 Nov 2026 · sale$1,14 m1 215$942,31
pitofsky jason4 Nov 2026 · sale$924 632982$941,58
pitofsky jason4 Nov 2026 · sale$540 765575$940,46
pitofsky jason4 Nov 2026 · sale$412 471439$939,57
zoghbi huda y3 Nov 2026 · sale$485 530500$971,06
zoghbi huda y3 Nov 2026 · sale$6,73 m6 939$970,42
larosa joseph j2 Nov 2026 · sale$509 140527$966,11
larosa joseph j2 Nov 2026 · sale$3,80 m3 939$965,41
sing george l2 Nov 2026 · sale$194 036200$970,18
sing george l2 Nov 2026 · sale$1,01 m1 040$967,07
sing george l2 Nov 2026 · sale$1,47 m1 522$966,27

SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.

About the company

Industry
Biotechnology
Exchange
NASDAQ
Country
US
IPO date
2 Apr 1991

Company description, revenue by segment and region, and the CEO will come later.

Next report
date not announced

An AI summary of the earnings call will come later.

Peers

CompanyPrice
MRNAModerna$215,2722would not consider—+13,1%−110,5%
VRTXVertex Pharmaceuticals$537,7972would consider33,7+10,5%30,7%
GILDGilead Sciences$167,5825would not consider—+6,5%−12,5%
AMGNAmgen$462,3267would watch26,8+8,2%24,1%
BIIBBiogen$251,6531would not consider107,8+2,3%3,4%
Compare with peers

Ratio — a score by our methodology, not an investment recommendation.